Should Airway Hyper-Responsiveness Be Included in the Definition of Clinical Remission With Biologic Therapy in Severe Asthma
Copyright © 2023 The Authors. Published by Elsevier Inc. All rights reserved..
Airway hyper-responsiveness (AHR) is a tenet of the persistent asthma phenotype along with reversible airway obstruction and type 2 (T2) inflammation. Indirect acting challenges such as mannitol are more closely related to the underlying T2 inflammatory process as compared with direct challenges. In this review article, we summarise the current literature and explore the future role of mannitol AHR in clinical remission with biologics.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2024 |
|---|---|
| Erschienen: |
2024 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:12 |
|---|---|
| Enthalten in: |
The journal of allergy and clinical immunology. In practice - 12(2024), 4 vom: 13. Apr., Seite 904-907 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Lipworth, Brian [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
3OWL53L36A |
|---|
| Anmerkungen: |
Date Completed 09.04.2024 Date Revised 26.04.2024 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1016/j.jaip.2023.12.013 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM365878634 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM365878634 | ||
| 003 | DE-627 | ||
| 005 | 20240427232022.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231227s2024 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1016/j.jaip.2023.12.013 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1390.xml |
| 035 | |a (DE-627)NLM365878634 | ||
| 035 | |a (NLM)38097177 | ||
| 035 | |a (PII)S2213-2198(23)01360-0 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Lipworth, Brian |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Should Airway Hyper-Responsiveness Be Included in the Definition of Clinical Remission With Biologic Therapy in Severe Asthma |
| 264 | 1 | |c 2024 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 09.04.2024 | ||
| 500 | |a Date Revised 26.04.2024 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Copyright © 2023 The Authors. Published by Elsevier Inc. All rights reserved. | ||
| 520 | |a Airway hyper-responsiveness (AHR) is a tenet of the persistent asthma phenotype along with reversible airway obstruction and type 2 (T2) inflammation. Indirect acting challenges such as mannitol are more closely related to the underlying T2 inflammatory process as compared with direct challenges. In this review article, we summarise the current literature and explore the future role of mannitol AHR in clinical remission with biologics | ||
| 650 | 4 | |a Review | |
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Airway hyper-responsiveness | |
| 650 | 4 | |a Asthma | |
| 650 | 4 | |a Biologic | |
| 650 | 4 | |a Remission | |
| 650 | 7 | |a Mannitol |2 NLM | |
| 650 | 7 | |a 3OWL53L36A |2 NLM | |
| 700 | 1 | |a Kuo, Chris RuiWen |e verfasserin |4 aut | |
| 700 | 1 | |a Stewart, Kirsten |e verfasserin |4 aut | |
| 700 | 1 | |a Chan, Rory |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t The journal of allergy and clinical immunology. In practice |d 2013 |g 12(2024), 4 vom: 13. Apr., Seite 904-907 |w (DE-627)NLM227247523 |x 2213-2201 |7 nnns |
| 773 | 1 | 8 | |g volume:12 |g year:2024 |g number:4 |g day:13 |g month:04 |g pages:904-907 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1016/j.jaip.2023.12.013 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 12 |j 2024 |e 4 |b 13 |c 04 |h 904-907 | ||